2020
DOI: 10.1186/s13619-020-00058-0
|View full text |Cite
|
Sign up to set email alerts
|

Mesenchymal stem cell as a novel approach to systemic sclerosis; current status and future perspectives

Abstract: Systemic sclerosis is a rare chronic autoimmune disease with extensive microvascular injury, damage of endothelial cells, activation of immune responses, and progression of tissue fibrosis in the skin and various internal organs. According to epidemiological data, women’s populations are more susceptible to systemic sclerosis than men. Until now, various therapeutic options are employed to manage the symptoms of the disease. Since stem cell-based treatments have developed as a novel approach to rescue from sev… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
5
4

Relationship

2
7

Authors

Journals

citations
Cited by 17 publications
(7 citation statements)
references
References 137 publications
(159 reference statements)
0
6
0
Order By: Relevance
“…They have the ability to self-renew and differentiate into a variety of mesenchymal lineages, including bones, cartilages, adipose tissues, and tendons. Furthermore, they can be isolated from a wide range of fetal and adult tissues (Larijani et al 2015 ; Goodarzi et al 2019a ; Abedi et al 2020 ; Aghayan et al 2020 , Ghezelayagh et al 2021 ; Islam et al 2021 ; Madani et al 2021 ; Xaki et al 2021 ; Aghayan et al 2022 ). Nowadays, this fact has been discovered that MSC therapy may inhibit the active immune system from triggering a cytokine storm in COVID-19 cases, and the stem cells' reparative powers may support endogenous repair (Ellison-Hughes et al 2020 ; Parhizkar Roudsari et al 2020 ; Rajarshi et al 2020 ; Arjmand et al 2021 , Gilany et al 2021 ).…”
Section: Therapeutic Interventionsmentioning
confidence: 99%
“…They have the ability to self-renew and differentiate into a variety of mesenchymal lineages, including bones, cartilages, adipose tissues, and tendons. Furthermore, they can be isolated from a wide range of fetal and adult tissues (Larijani et al 2015 ; Goodarzi et al 2019a ; Abedi et al 2020 ; Aghayan et al 2020 , Ghezelayagh et al 2021 ; Islam et al 2021 ; Madani et al 2021 ; Xaki et al 2021 ; Aghayan et al 2022 ). Nowadays, this fact has been discovered that MSC therapy may inhibit the active immune system from triggering a cytokine storm in COVID-19 cases, and the stem cells' reparative powers may support endogenous repair (Ellison-Hughes et al 2020 ; Parhizkar Roudsari et al 2020 ; Rajarshi et al 2020 ; Arjmand et al 2021 , Gilany et al 2021 ).…”
Section: Therapeutic Interventionsmentioning
confidence: 99%
“…Also, according to research, administering neurotrophic or neuroprotective agents like 7,8-dihydroxyflavone or glycoprotein non-metastatic protein B can promote neuronal regrowth and neuronal repair (39,45). Furthermore, some studies have focused on the role of cell-based therapies for neurodegenerative diseases (51)(52)(53).…”
Section: Microbiotamentioning
confidence: 99%
“…Further studies are needed for optimal preparation of MSC infusions and long-term data collection essential to determine the long-term risks of MSC. Although, the risk for interstitial lung disease or accelerated fibrosis initially was a great concern - for the potential of trapped MSC within the lung to differentiate into fibroblasts -, this, so far, has not been a reported adverse effect ( 70 ). Further studies are needed for optimal preparation of MSC infusions and long-term data collection essential to determine the long-term risks of MSC.…”
Section: Safety Data For Msc Based Therapiesmentioning
confidence: 99%
“…There is significant interest in MSC treatment of SSC for the paucity of effective treatment options, as well as, for the pathogenesis of the illness that is tightly coupled with the progeny of MSC, i.e., fibroblasts and endothelial cells ( 70 ). Initial results were encouraging on a small case series of four patients with leukemia who developed sclerodermatous chronic GVHD after bone marrow transplant ( 80 ).…”
Section: Msc Treatment Of Autoimmune Diseases—overview Of Publish Datamentioning
confidence: 99%